Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - michael+mitchell
17
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Reducing The Adverse Side Effects Of Using Native T-Cells To Destroy Cancer Cells
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected. Problem: Compounds which link native T-cells with the surface antigens found on cancer cells have emerged as an effective treatment for blood malignancies and are currently being developed for solid tumors....
Published: 12/8/2025
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
,
Protein/Peptide (Non-Antibody)
,
Small Molecule
Category(s):
Technology Classifications > Therapeutics
Targeted, Enhanced Modification Of Lipid NanoparticlesTto Improve Tumor Therapeutic Efficacy
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors. Problem: Lipid nanoparticles (LNPs) have shown promise as drug delivery systems for various diseases with several clinically approved products. However, their ability to deliver genes specifically to tumor cells...
Published: 11/26/2025
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
,
Wenqun Zhong
,
Wei Guo
Keywords(s):
Bioengineering
,
Drug Delivery
,
Immunoncology
,
Oncology
Category(s):
Technology Classifications > Therapeutics
Biocompatible And Low-Toxicity Lipid Nanoparticles (LNPs) For Selectively Delivering mRNA To The Bone Microenvironment
Ionizable LNPs with a rigid backbone of piperazine (PIP) linked to bisphosphonates (BPs) for the targeted delivery of mRNA to the bone. Problem: Available treatments for bone tissue related diseases provide only symptomatic relief and are associated with clinical challenges and potential side effects. Challenges persist in the delivery of therapeutic...
Published: 10/3/2025
|
Inventor(s):
Michael Mitchell
,
Kyle Vining
,
Lulu Xue
,
Il-Chul Yoon
Keywords(s):
Aging
,
Bioengineering
,
Drug Delivery
,
Gene Therapy
,
Orthopedics
,
Platform Technology
,
Women's Health
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 11/26/2025
|
Inventor(s):
Ann Metzloff
,
Margaret Billingsley
,
Michael Mitchell
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Prodrug Lipid Nanoparticles for Synergistic Cancer Immunotherapy
Prodrug lipid nanoparticle (LNP) with a mRNA encoding for a therapeutic cytokine for solid tumor immunotherapy.</brief> Problem: Approximately 2 million people are diagnosed with cancer each year in the United States. Messenger RNA (mRNA)-based cancer immunotherapy has emerged as a potential cancer treatment using cytotoxic T cells to eliminate...
Published: 12/8/2025
|
Inventor(s):
Michael Mitchell
,
Qiangqiang Shi
Keywords(s):
Bioengineering
,
Drug Delivery
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/8/2025
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Cell Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
Overcoming the Blood-Brain Barrier with Peptide-Functionalized Lipid Panoparticles
Peptide-functionalized lipid nanoparticles (pLNPs) for targeted messenger RNA (mRNA) delivery to the brain. Problem: Ionizable lipid nanoparticles (LNPs) have emerged as clinically advanced delivery vehicles for nucleic acids. However, as LNPs typically accumulate to the liver, tissue-specific delivery remains challenging, and systemic LNP delivery...
Published: 12/8/2025
|
Inventor(s):
Michael Mitchell
,
Emily Laura Han
Keywords(s):
Bioengineering
,
Drug Delivery
,
Neurodegenerative Diseases
Category(s):
Technology Classifications > Therapeutics
Lipid Nanoparticles That Specifically Target The Lungs
Lung-targeting lipid nanoparticles allowing organ specific mRNA delivery for gene therapy applications. Problem: Gene therapy via mRNA delivery allows the rapid generation of therapeutics and vaccines for a wide range of applications. However, mRNA is especially vulnerable to degradation in the body, necessitating packaging within lipid nanoparticles....
Published: 11/26/2025
|
Inventor(s):
Michael Mitchell
,
Lulu Xue
Keywords(s):
Bioengineering
,
COVID-19
,
Gene Therapy
,
Infectious Disease
,
Pulmonary
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
,
Technology Classifications > Vaccines
Ionizable Lipid Nanoparticles with Low Immunogenicity Which Enable Repeated Administrations of mRNAs Encoding Gene Editors, Tumor Neoantigens, and Vaccine Payloads.
Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery. Problem: Lipid nanoparticle (LNP)-based delivery systems for mRNA-based therapeutics have recently demonstrated their clinical success in applications such as ONPATTRO® and the Pfizer/BioNTech and Moderna COVID-19...
Published: 10/3/2025
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Drug Delivery
Category(s):
Technology Classifications > Therapeutics
Safe and Potent mRNA Lipid Nanoparticles (LNPs) for Ex-Vivo Engineering of Immunosuppressive T cells in Autoimmunity Therapies.
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties. Problem: Autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, and myasthenia gravis) are mediated by self-reactive lymphocyte (B or T cells) expansion. Available suppressive medications like...
Published: 11/26/2025
|
Inventor(s):
Michael Mitchell
,
Ajay Thatte
,
Alvin Mukalel
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunology
,
Immunotherapy
,
Platform Technology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
1
2